Overview

A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria

Status:
Completed

Trial end date:
2008-02-01

Target enrollment:
0

Participant gender:
All

Summary

The treatment of symptomatic, uncomplicated malaria caused by P. falciparum in adults.

Phase:

Phase 2

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Pfizer

Treatments:

Azithromycin
Chloroquine
Chloroquine diphosphate

Criteria

Inclusion Criteria:

- Males and females greater then or equal to the age of 18 with uncomplicated,
symptomatic malaria as indicated by the presence of blood smears positive for P.
falciparum asexual parasitemia between 1000-100,000 parasites/uL and documented fever
greater then or equal to 38.5 C/101.3 F rectal or fever greater then or equal to 38
C/100.4 F oral or history of fever as reported by subject within the prior 24 hours.

Exclusion Criteria:

- Subjects with severe or complicated malaria. Pregnant or breast feeding women.